Single-center, Randomized, Double-blind, Single-dose, 3-way Crossover Study to Compare the Effects of Daridorexant and Placebo on Postural Stability, the Auditory Awakening Threshold, and Cognitive Function in the Middle-of-the-night Following Evening Administration to Healthy Adult and Elderly Subjects
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 03 Jun 2024 According to an Idorsia Pharmaceuticals media release, data form this study will be presented at the SLEEP 2024 - the 38th Annual Meeting of the Associated Professional Sleep Societies, taking place in Houston, Texas, from June 1- 5, 2024.
- 17 Apr 2023 Status changed from recruiting to completed.
- 31 Jan 2023 New trial record